Lactam Chemistry: Iceland's Niche Import from Indian Makers

Specialty lactam compounds—chemical building blocks for advanced antibiotics and anti-cancer drugs—just emerged as a new export arena for India's chemical makers. The market move from zero in 2024 to $526,000 in 2025 reveals how aggressively TEPA's duty eliminations are unlocking niche chemistry corridors that existed only on paper before the trade pact took effect.

A Chemical Corridor Materializes: Zero Duties Transform Opportunity

When India's Trade and Economic Partnership Agreement (TEPA) with the European Free Trade Association entered into force on 1 October 2025, EFTA committed to eliminate customs duties on 92.2 percent of tariff lines, comprising 99.6 percent of India's export value to EFTA at zero customs duty. For specialty pharmaceutical intermediates, that elimination meant removing all barriers to entry for a product class that previously faced tariff walls across Iceland and other Nordic markets.

The result: India's lactam compound shipments to Iceland surged from nothing in 2024 to $525,901 in 2025—a shipment that went to market only because the duty was eliminated. India captured 99.31 percent of Iceland's total import demand for this product, establishing immediate dominance in a niche but critical chemistry segment.

"The agreement will provide Indian exporters better access to high-income markets in Europe and also open an investment pathway worth $100 billion over the next 15 years."

Which Companies Are Seizing the Opening

Akums builds a varied portfolio of small molecule pharmaceutical ingredients across niche areas including beta-lactams and non-beta-lactams, positioning it as a direct beneficiary of TEPA's zero-duty access. Similarly, Divi's Laboratories is the world's largest manufacturer of more than 10 generic active pharmaceutical ingredients, giving the company substantial reach into Nordic specialty markets once duties vanished. Sun Pharma, Aurobindo Pharma, and Cipla rank among the top API manufacturers in India, all known for quality, compliance, and export capabilities—strengths that translate directly into confidence among Nordic buyers seeking regulated suppliers.

The supply chain runs through India's three dominant chemical clusters. Genome Valley in Hyderabad operates as a premier biotech cluster with world-class infrastructure, where Divi's Laboratories anchors activity as a global leader in active pharmaceutical ingredients. Ahmedabad is a major center for bulk drug manufacturing and generic medicines, with companies like Zydus Cadila and Torrent Pharma headquartered there. And Baddi, located in the Solan district of Himachal Pradesh, is India's largest pharmaceutical manufacturing hub by volume, hosting major players like Dr. Reddy's, Cipla, Sun Pharma, and Torrent. Each cluster brought existing infrastructure, regulatory certifications, and export logistics into the lactam production pipeline the moment TEPA duties fell to zero.

Tariff Cuts That Triggered Entry: Before vs. After TEPA

Pre-TEPA, Iceland likely levied baseline MFN (most-favored-nation) tariff rates on specialty organic chemicals—rates that, while not prohibitive for large-volume commodities, created friction for niche pharmaceutical intermediates where margins are narrower and regulatory premiums are high. In chemicals, plastics, and allied sectors, the agreement offers zero or reduced tariffs on 95 percent of Indian exports, with pre-FTA duties in these sectors as high as 54 percent, while post-agreement exports are projected to grow from USD 49 million to over USD 70 million. The lactam opportunity mirrors this pattern: zero duties replaced existing tariffs, eliminated price sensitivity for Nordic formulators, and allowed Indian producers to win supply relationships overnight.

The $526,000 shipment entered duty-free. Under earlier tariff regimes, that same shipment would have absorbed duty costs sufficient to make Indian producers uncompetitive against European (particularly Swiss and German) lactam suppliers already holding Nordic market share.

Supply Chain: From Hyderabad and Ahmedabad Factories to Reykjavik's Pharmaceutical Doors

India is the world's third-largest pharmaceutical producer by volume and fourteenth by value, with more than 3,000 companies and 10,500 manufacturing units, with Indian medicines reaching over 200 markets worldwide, with the United States accounting for about 34 percent and Europe about 19 percent of India's pharmaceutical exports. The lactam trade to Iceland follows this same path: synthesis occurs in API facilities in Telangana and Gujarat, regulatory documentation flows through Pharmexcil (the official export promotion body), and shipments move via Mumbai or other major ports directly to Reykjavik, where Nordic pharmaceutical formulators—manufacturers of antibiotics, anti-cancer medicines, and immunosuppressants—integrate them into finished products.

One shipment of lactam intermediates to Iceland may feed into production runs supplying not just Iceland's small pharmaceutical sector but the broader Nordic market served by regional distributors. The duty-free entry means Indian suppliers can now bid against Swiss, German, and Scandinavian competitors at price points that previously were unattainable.

Competitive Landscape: India Seizes a Niche Where Belgium Once Led

Before TEPA, Iceland's lactam imports were marginal. The 2025 data reveals Belgium and Estonia as secondary suppliers, each taking less than 0.2 percent of Iceland's market. China appeared only as a minimal source, held back by regulatory compliance scrutiny for pharmaceutical intermediates. India's entry at 99.31 percent market share in a newly opening corridor signals that TEPA didn't merely reduce friction—it created a preference hierarchy favoring Indian suppliers whose cost advantage, FDA compliance density, and manufacturing scale are unmatched in this niche.

Jobs, Communities, and MSME Participation

The pharmaceutical chemical sector is deeply rooted in India's MSME ecosystem. At least 80 percent of Indian pharmaceutical companies qualify as MSMEs, and approximately 30 percent of pharmaceutical sector employment is held by women—a testament to the sector's role as an employment engine in regions like Hyderabad, Ahmedabad, and Baddi where family-scale and small-batch operations thrive alongside large conglomerates.

To estimate employment supported by the lactam trade route: Using the sector multiplier of 3.5 direct jobs per $100,000 in pharmaceutical exports, the current $525,901 lactam trade supports approximately 18 direct jobs in Indian API facilities. The indirect multiplier—9 jobs per $100,000 across supply chain, logistics, and support services—yields an additional 47 indirect jobs in Hyderabad, Ahmedabad, and surrounding industrial clusters. This means roughly 65 livelihoods are now sustained by a product category that did not ship to Iceland in 2024.

As the lactam corridor expands from its $526,000 base, each additional $1 million in export value will add approximately 12 direct and 9 indirect jobs—primarily benefiting Telangana's Genome Valley, where Ahmedabad and other cities like Bangalore, Pune, and Gujarat also contribute significantly to India's pharma industry. Female participation in manufacturing, quality assurance, and regulatory roles—already at 30 percent sector-wide—stands to rise as Nordic demand for Indian intermediates grows.

What's Next: The Phased Tariff Schedule Unlocks Additional Products

Some tariff eliminations under TEPA will be removed immediately once TEPA came into force on October 1, 2025; others will be phased out over three, five, seven, or 10 years. The lactam trade benefited from immediate duty elimination. But the full potential of TEPA for India's chemical exporters remains in the unfolding phaseout schedule. Organic chemicals, specialty chemicals, and intermediates will face lower tariff barriers in EFTA states, giving Indian chemical exporters access to niche industrial markets. As those tranched reductions take effect over the next decade, Indian producers of advanced intermediates for anti-infectives, oncology, and rare-disease medicines will gain entry to an expanding portfolio of EFTA markets.

The lactam story in 2025 is the proof of concept: eliminate duties, and Indian chemical makers will seize the corridor within months, establish supply relationships, and dominate through cost, compliance, and scale.